28.23 USD
▲+0.20+3.52%
盘后 27.59 +1.16%
2026-08-03
市值
$1.10B
市盈率
—
EPS
-2.45
股息率
—
52 周区间
3.00 – 28.85
成交量
555.44K
Beta
1.07
目标价
35.13
52W 低 3.0052W 高 28.85
价格走势
公司简介
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 pro...